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Individuals with Down Syndrome (DS) show significant development and aggressive 
progression of Alzheimer’s disease (AD) at a significantly earlier age than neurotypical 
individuals. The risk of AD is also particularly high in women with DS; it is even higher than the 
risk of AD in neurotypical women, which in turn, is higher than the risk of AD in neurotypical 
men. The DS population, as a whole, has a lower hippocampal volume and a higher prevalence 
of obesity when compared to the neurotypical population. This study examined the relationship 
between BMI and hippocampal volumes in women with DS. MRI imaging, demographic data, 
and physical assessment data from women with DS aged 40-59 were obtained from the 
Alzheimer’s Biomarker Consortium -Down Syndrome (ABC-DS) study database and were 
examined to evaluate the relationship between BMI and hippocampal volume. FreeSurfer was 
used to extract hippocampal volume from MRI images and BMI was calculated for each 
subject. The results suggested that BMI was not related to hippocampal volumes. However, 
ventricular volumes were negatively related to BMI suggesting that a higher BMI may be 
protective for the DS brain. Given the earlier onset and higher risk of AD in female subjects with 
DS and their higher prevalence of obesity, the data analyzed from subjects in this population may 









Alzheimer’s Disease and Down Syndrome 
 Down Syndrome is a genetic disorder caused by the trisomy of the 21st chromosome 
(Wiseman et al., 2015). As a result of this trisomy, there is an extra copy of the gene encoding 
amyloid precursor protein (APP), a precursor to the neurotoxic protein amyloid beta (Aβ). APP 
is cleaved to form amyloid beta (Aβ), which instigates the progression of AD through the 
formation of amyloid cascade neuropathology (Schupf et al., 2018). This neuropathology is 
mainly characterized by neurofibrillary tangles, and high intracellular levels of the neurotoxic 
protein Aβ, directly resulting in the deposition of Aβ plaques. Aβ in its soluble and insoluble 
forms increases neuroinflammation, oxidative stress, and neuronal death; all of the 
aforementioned detriments are more prevalent in populations with DS, even before the definitive 
onset of AD neuropathology (Head et al., 2016). The higher prevalence of these factors is 
hypothesized to be a result of the dosage difference, caused by the extra copy of the APP gene. 
Consequently, populations with DS have a higher risk and earlier onset of AD (Schupf et al., 
2006; Schupf et al., 2018). 
 In the general population of the U.S., there are 3.3 million cases of AD in women and a 
total of 5.2 million cases of AD, meaning that women constitute approximately two thirds of the 
total AD population (Pike, 2017; Oveisgharan et al., 2018). The reason for the imbalance in 
cases is still unclear, though it may be due to a combination of factors including women’s loss of 
estrogen at menopause, their longer life expectancy, and their increased levels of tau tangles 
(Oveisgharan et al., 2018). AD in populations with DS is different from AD in neurotypical 
populations in that there is no sex difference involved in risk of AD in DS populations (Wiseman 
et al., 2015). These aberrancies between DS and neurotypical populations with AD may be due 




to the duplication of the 21st chromosome which causes inherent hormonal and cardiovascular 
differences in people with DS (Schupf et al., 2006; Schupf et al., 2003; Wiseman et al., 2015). 
The research findings are unclear regarding the timeline of AD progression in DS 
individuals. Lott and Head (2019) conducted a study in which nearly all individuals with DS 
developed neuropathological changes indicative of AD by the age of 40 (Lott & Head, 2019; 
Rubenstein et al., 2020). Conversely, a 2015 study conducted by Wiseman et. al, stated that, at 
the age of 40, less than 5% of individuals with DS had developed AD. Furthermore, from the age 
of 40-60, the risk of developing AD doubles every five years (Wiseman et al., 2015). Lastly, a 
study from Annus et al. (2017) claimed that the onset of AD neuropathology generally occurred 
at the age of 50 (Annus et al. 2017). While there is still debate about the exact age of onset, it is 
clear that age is a major risk factor for AD in people with DS, beyond what is seen in 
neurotypical populations.  
Down Syndrome in AD and Hippocampal Volume 
As the AD process causes widespread atrophy in the brain, one of the key targets for 
pathophysiological change is the hippocampus, a location vital to memory and learning (Laakso 
et al., 2000). Hippocampal atrophy begins early in AD, particularly at its frequent point of 
origination in the entorhinal and trans-entorhinal cortices (Raji et al., 2009). In early AD, the 
majority of the atrophy affects the anterior hippocampal horn, a portion heavily implicated in 
memory processing (Ho et al., 2011; Laakso et al., 2000). Later in the disease progression, the 
posterior hippocampus becomes the primary site of atrophy.  
Interestingly, even in the absence of AD neuropathology, DS has been associated with 
lower hippocampal volumes, as illustrated in Figure 1, and enlarged ventricles (Annus et a., 
2017). The lateral ventricles are located in the vicinity of the hippocampus, while the inferior 




portion of the lateral ventricle directly borders the lateral side of the hippocampus (Fogwe et al., 
2021). Due to the proximity of the ventricles to the hippocampus, they may be useful as an 
indirect measure of hippocampal atrophy, general cortical atrophy, or both. The lower 
hippocampal volumes found in individuals with DS is not surprising, considering that 
populations with DS also have a lower total brain mass and volume, more shallow gyri and sulci, 
and fewer neurons in the adjacent temporal lobes (Dierssen, 2012; Ho et al., 2011). Due to the 
decreased size of these structures, it is important to note that changes in hippocampal volume 
may be more subtle due to lower overall brain volume in DS brains. Besides these inherent 
structural differences in the period before amyloid deposition, AD progression in DS populations 
is very similar to AD in the general population (Annus et al., 2017).  
Estrogen and AD in Down Syndrome 
Although there is no sex difference in AD risk in DS populations, women with DS may 
have an element of neuroprotection that is not present in men with DS (Tyrrell et al., 2001; 
Schupf et al., 2006). Endogenous bioavailable estrogen is one factor that may reduce the risk of 
AD and attenuate aggressive neurodegeneration. Estrogens have been known to have numerous 
neuroprotective effects and may be helpful in fighting the progression of AD (Schupf et al., 
2006). The benefits of estrone, a type of estrogen, include protection against the toxicity of Aβ, 
activation and maintenance of neuronal health in the cholinergic system, anti-inflammatory and 
antioxidant properties, and the facilitation of the non-amyloidogenic metabolism of APP, a 
precursor to Aβ (Behl et al., 1995;  Toran-Allerand et al., 1992; Xu et al., 1998; Hosoda et al., 
2001).  
The loss of estrogen in postmenopausal women and the ensuing cognitive decline is 
considered an indication of a correlation between bioavailable estrogen and cognition (Yaffe et 




al., 2000; Schupf et al., 2018). Earlier menopausal events and lower levels of bioavailable 
estrogen have been shown to increase the risk of AD and to expedite its onset (Schupf et al., 
2018). It is important to note that most women with DS experience an onset of AD decades 
earlier than neurotypical populations; the age of onset of AD in the general population is 
normally after 75 years old, while in populations with DS, it is often present around the age of 
35. Similarly, women with DS enter menopause at an average age of 44-46 compared to the 
average age of 51 in neurotypical women (Schupf et al., 2006; Schupf et al., 2017). The shorter 
period of time between menopause and the onset of AD in DS populations may enable 
researchers to study the effects of menopausal events on the risk and onset of AD with a 
decreased confounding effect caused by age  (Schupf et al., 2018).  
Body Mass Index and AD in Down Syndrome 
Body mass index (BMI) is a ratio between weight and height, often used as an indication 
of weight and health status (King, 2007; Schupf et al., 2006); it is another factor that has been 
linked to AD risk and prevention and has been positively correlated with levels of estrone and 
estradiol, another type of estrogen. As well as being indirectly linked to cognition through 
estrogens, BMI has been directly associated with cognition in a study involving postmenopausal 
women with DS (Patel et al., 2004). Subjects who were categorized as obese (BMI ≥ 30 kg/m²) 
performed significantly better on tests of verbal memory and neuropsychological function than 
non-obese women (Patel et al., 2004; Caballero et al., 2019). Through its association with higher 
levels of endogenous estrogen and higher scores on tests of cognitive function, BMI is an 
important factor to consider in AD research.  
BMI is an especially relevant factor in people with DS because they have a significantly 
higher incidence of obesity, and therefore, a higher BMI than the general population (Wong et 




al., 2014). There is also a sex difference involving BMI in people with DS; the prevalence of 
obesity is 11% higher in women with DS than in men with DS (Wong et al., 2014). While the 
disparity between obesity in people with DS and the general population is predominantly due to 
environmental and lifestyle factors, people with DS also have physiological factors such as low 
muscle tone, low metabolism, and hypothyroidism that predispose them to obesity (Wong et al., 
2014). While higher BMIs have been linked to higher levels of the endogenous estrogen which 
can foster healthy cognition and reduce AD risk, BMI has also been correlated with lower 
cardiovascular health, which is a risk factor for AD (Gustafson et al., 2003; Schupf et al., 2006; 
Wong et al., 2014). In addition to increasing the risk of AD, obese individuals will likely 
succumb to the characteristic neurodegenerative processes of AD more easily due to poor 
cardiovascular health (Ho et al., 2011). Women with DS have significantly earlier menopausal 
events and AD onset, along with higher BMIs and reduced hippocampal volumes (Annus et al., 
2017; Schupf et al., 2003; Wong et al., 2014). Consequently, women with DS are an important 
population in which to study the interactions of BMI with AD risk and neuropathology. 
While BMI has been linked to AD progression in DS populations, it has similar effects on 
AD progression in the neurotypical population, in addition to being associated with hippocampal 
volume. BMI is inversely correlated with hippocampal volume in the early stages of disease-
related cognitive impairment in neurotypical adults, suggesting that obese individuals are more 
vulnerable to the disease process (Ho et al., 2011). This may be because of the detrimental 
effects of obesity on cardiovascular health, which leads to neurovascular insufficiency in both 
DS and neurotypical populations (Ho et al., 2011; Wong et al., 2014). An unhealthy 
cardiovascular system and the overall poor health that it leads to can allow the disease process to 
continue uninhibited and encourage hippocampal atrophy, specifically in the anterior portion (Ho 




et al., 2011). In the later stages of AD, when the posterior hippocampus is the main target of 
atrophy, BMI is directly correlated with hippocampal volume in neurotypical individuals (Ho et 
al., 2011). While this seems to suggest that BMI is beneficial to fighting the AD process, there 
are a number of confounding factors; the more advanced stages of AD are associated with lower 
BMI, partially because of the effect that cognitive impairment has on eating habits, and partially 
because of a decline in self-care and caregiver intervention (Wang, 2002). Thus, the association 
between BMI and late hippocampal atrophy is not a reliable indication of BMI’s effect on 
cognition in AD. Conversely, in the early stages of AD where the individual is mildly 
cognitively impaired, BMI seems to have a detrimental effect on the brain’s defense against the 
progression of AD (Ho et al., 2011). Since BMI is correlated with hippocampal volume in the 
neurotypical population, it is possible that these two factors are also linked in the DS population. 
The higher prevalence of obesity and AD in women with DS, and the association 
between BMI and hippocampal volume in neurotypical populations are characteristics that are 
pivotal to this study. Combined with the shorter time period between menopause and the onset of 
AD, women with DS are an important population in which to consider the effects of BMI on 
hippocampal volume. Research in women with DS presents a unique opportunity to gain insights 
into AD progression in a population that is disproportionately burdened with the disease and 
particularly vulnerable to its effects. I hypothesize that BMI will be negatively related to 










This study analyzed demographic information, physical assessments, and neuroimaging 
data from 36 women from 40-59 years old with DS in the ABC-DS database. Data were 
requested from the ABC-DS study, which includes the Neurodegeneration in Aging Down 
Syndrome (NiAD) and Alzheimer’s Disease in Down Syndrome (ADDS) study sites. These data 
had been collected 3-4 times periodically over the 5-year course of the study. The NiAD study 
had 180 subjects who were 25 years and older, while there were 220-225 adults who were 40 
years and older in the ADDS study. In total, there was available data on at least 400 participants, 
and it was expected that approximately 200 subjects would be female. The height and weight 
values in the physical assessment data were used to calculate a BMI for each participant. The 
neuroimaging database was searched using the following specifications: Study=ABCDS, 
Age=25-75, Group=DS, Visit=Baseline, Weighting=T1, and Acquisition=3D. Once the 323 
results were reviewed, 134 were chosen based on quality of the image. Subjects aged 40-75 were 
selected for volumetric analysis via Freesurfer software. The hippocampal volume of participants 
with a normal BMI (BMI ≥ 18.5-24.9 kg/m²) was compared to participants with BMIs indicating 
overweight (BMI ≥ 25-29.9 kg/m²) and obese (BMI ≥ 30 kg/m²) individuals and ANOVA 
models were used to compare across the two groups. Correlations were run between subject 
hippocampal volume and BMI. P-values were obtained for each correlation. Descriptive statistics 











The subjects were 36 women with DS aged 40-59 years. There was a total of 35 subjects 
(n=35) with both demographic data and FreeSurfer volumetric analysis data and one subject 
(n=1) with only the FreeSurfer data. The subject without associated demographic data was not 
included in the statistical analysis. Subjects were categorized as premenopausal or 
postmenopausal, and there were 16 premenopausal women and 19 postmenopausal women. The 
subjects were also categorized by their dementia status: no Mild Cognitive Impairment (MCI) 
and no dementia, MCI, and dementia. There were 29 study subjects in the no dementia and no 
MCI group, two subjects in the MCI group, and four subjects in the dementia group. The BMIs 
of the subjects ranged from 21.82-51.85 kg/m2. Each BMI was categorized as normal (BMI ≥ 
18.5-24.9 kg/m²), overweight (BMI ≥ 25-29.9 kg/m², or obese (BMI ≥ 30 kg/m²). There were 
three subjects with a normal BMI, 10 subjects with an overweight BMI, and 22 subjects with an 
obese BMI. 
BMI and Hippocampal Volume 
 The relationship between BMI and hippocampal volume was examined. There were no 
correlations between BMI and the right hippocampus (r= .281, p=.10) or the left hippocampus 
(r=.191, p=.27). While BMI was not correlated to hippocampal volume, it was found to be 
correlated with the volumes of the right inferior lateral ventricle, (r=-.35, p=.04), left inferior 
lateral ventricle, (r=-.34, p=.04) and right lateral ventricle, (r=-.38, p=.03). 
A one-way ANOVA test was utilized to compare the hippocampal volumes for subjects 
in each of the dementia status groups.  The mean volumes of the right hippocampus (F(2,32) = 
11.91, p=<.001), and left hippocampus, (F(2,32) = 7.36, p=.002) were significantly different 




between dementia status groups. Descriptive statistics were obtained for each dementia status 
group and are presented in Table 1. The mean volumes show that both hippocampi were smaller 
in MCI and AD groups.   
Regressions were run for both hippocampal volumes with age and BMI as predictors to 
account for the effects of both variables on hippocampal volumes. The overall model of age and 
BMI explained a significant amount of variance in left hippocampal volume, R2=.25, 
F(2,32)=5.39, p=.01. BMI was not a significant predictor of left hippocampal volume, b=.11, 
t(32)= 0.70, p=.49. However, age was a significant predictor of left hippocampal volume, b=-.47, 
t(32)=-3.04 p=.01. 
Similarly, the overall model of age and BMI explained a significant amount of variance 
in the right hippocampal volume R2=.25, F(2,32)=5.34, p=.01. BMI did not significantly predict 
the volume of the right hippocampus, b=.21, t(32)=1.34, p=.19, and age was a significant 
predictor of right hippocampal volume, b=-.42, t(32)=-2.71 p=.01. 
Menopause Status and Hippocampal Volume  
Hippocampal volumes were compared between premenopausal and postmenopausal 
groups. An independent samples t-test found a significant difference between the premenopausal 
and postmenopausal groups in measures of left hippocampus (t(33)=2.68, p=.01), and right 
hippocampus (t(33)=2.54, p=.02). Descriptive statistics were also obtained; as shown in Table 2, 
premenopausal women showed consistently higher mean hippocampal volumes than 
postmenopausal women. 
Discussion 
 The main finding of this study was that there were no relationships between BMI and 
hippocampal volume. However, there were a number of significant findings that may provide 




insight into the mechanisms of age- and dementia-related brain changes in women with DS and 
provide future directions for AD research in DS populations. 
 Both BMI and hippocampal volume are important factors to consider in research on 
women with DS and AD. It was hypothesized that BMI would influence the volume of the 
hippocampus in a sample of middle-aged and older women with DS. The data did not support 
this hypothesis; the data suggested that BMI was not related to hippocampal volume. However, 
there may be an alternative explanation, given the conflicting interactions of BMI with AD risk 
and progression. It is possible that the cardiovascular benefits and detriments of high BMI 
neutralize each other, resulting in no net effect on AD (Schupf et al., 2006). An increased BMI 
has been associated with higher levels of endogenous estrogen and higher performances on 
measures of cognitive function in women with DS (Patel et al., 2004; Schupf et al., 2006). Yet 
high BMI has also been known to decrease cardiovascular health, which hinders the brain’s 
ability to fight AD progression. Considering the fact that no relationship was found between 
BMI and hippocampal volume despite the many connections between AD progression and BMI, 
it is likely that these opposite effects of BMI balance each other out. As a result, there was no 
overall effect on hippocampal volume.  
Due to their proximity to the hippocampus and enlargement during cortical atrophy in 
AD, ventricular volume may be used as an indirect measure of hippocampal and medial temporal 
region volume. When a correlation was run between BMI and ventricular volume, the volumes 
of both inferior lateral ventricles and the right lateral ventricle showed a negative correlation 
with BMI. As previously noted, hippocampal changes in individuals with DS may be more 
difficult to detect, due to their smaller hippocampi prior to any AD-induced atrophy (Annus et 
al., 2017). Since the lateral and inferior lateral ventricles are located in the vicinity of the 




hippocampi, even subtle hippocampal atrophy might be suggested by larger ventricular volumes 
(Fogwe et al., 2021). The ventricular enlargement may be caused by the atrophy of other AD-
related structures, but due to the proximity of the hippocampi and their consistent atrophy in 
early and advanced stages of AD, it is possible that general volume changes in this medial 
temporal region may have contributed to the ventricle enlargement found in this study. 
Furthermore, as AD progresses into the later stages, it is associated with both larger ventricles 
and a lower BMI (Thompson et al., 2004; Wang, 2002).  
Hippocampal volumes were also examined across the three dementia status groups. The 
mean hippocampal volume was significantly different between the groups with no MCI or AD, 
MCI, and AD. The mean hippocampal volume was smaller in groups with a more advanced 
stage of dementia. These expected findings illustrate the increasing hippocampal atrophy that is a 
defining trait of AD. Therefore, the decreasing size in hippocampal volume across disease status 
shown by these data is completely consistent with the normal progression of AD.  
Menopause status was also used to examine hippocampal volume of women with DS. 
There was a difference between the hippocampal volumes of pre-menopausal and 
postmenopausal women with DS. This was an expected finding considering that menopause 
status is a proxy measure for age and age is a prominent risk factor for AD (Wiseman et al., 
2015).  
Although there was no relationship between BMI and hippocampal volume, this finding 
may still inform future AD research in DS populations. In addition to hippocampal volume, this 
study examined the relationships between menopause, dementia status, and ventricular volume 
and BMI. Further studies with larger numbers of women with DS are likely to provide more 




information about the relationships between BMI, brain volume, menopause, and dementia 
status. 
Limitations 
The reliability and implications of the results are limited by the sample size of the study. 
Due to the time constraints of this project and the time-intensive process of running the subjects 
through the FreeSurfer software, the sample size was small.  However, power calculations 
showed that the sample size had sufficient statistical power to detect a correlation of 0.30. 
Continuing these analyses with the rest of the sample available in the ABC-DS database would 
be the first step in examining the relationship between structural brain imaging measures and 
BMI in women with DS.   
Conclusion 
 There are still a plethora of unknowns concerning the interactions of BMI and AD 
neuropathology in DS populations. This study focused specifically on examining the relationship 
between hippocampal volume and BMI in women with DS. While no relationship was found 
between these two variables, a more severe dementia status was associated with smaller 
hippocampal volumes. Also, postmenopausal women had smaller hippocampal volumes than 
premenopausal women. These results are consistent with previous research and illustrate the 
normal progression of AD in people with DS. It is important to explore the other avenues that 
may account for neuropathological and clinical differences between AD in the general 
population and AD in people with DS. Information vital to AD prevention and treatment may lie 
in the comparison between these differing presentations of AD.  
 
 





In addition to repeating this study with a larger sample size, there are a few areas for further 
study that may be useful in elucidating the relationship between BMI and AD in individuals with 
DS. One idea for further study is to examine the relationship of BMI and hippocampal volume in 
groups of subjects with varying stages of AD. Since BMI decreases in the later stages of AD, any 
correlation in that group would be expected, but it would be interesting to track any associations 
between BMI and hippocampal volume throughout the progression of AD. The sample size of 
this study was too small to carry out these analyses for each dementia status group. BMI and 
hippocampal volume could also be studied in men with DS. Without the neuroprotective effects 
of estrogen, as seen in women with DS, higher BMIs may be associated with lower hippocampal 
volumes.   
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Figure 1. Figure 1 shows four coronal slices of the brain at the level of the 
hippocampus. Figure 1a shows hippocampal atrophy in a neurotypical brain with 
AD. Figure 1b shows a normal hippocampus in a neurotypical brain. Figure 1c 
shows hippocampal atrophy in an ABC-DS subject with DS. Figure 1d shows 
hippocampal atrophy in an ABC-DS subject with DS and AD.  












Table 1. The descriptive statistics for the comparison of hippocampal volumes and dementia 
status. 
Dementia Status Right Hippocampal Volume Left Hippocampal Volume 
No MCI and No Dementia (0) 3240.3(453.6) 3010.9(421.5) 
MCI (1) 2497.8(137.3) 2496.3(53.0) 
Dementia (2) 2166.6(451.80) 2227.0(383.0) 
 
  





Table 2. The descriptive statistics for the comparison of hippocampal volumes between pre-
menopausal and post-menopausal groups. 
Menopausal Status Right Hippocampal Volume Left Hippocampal Volume 
Pre-menopausal (0) 3324.3(590.2) 3111.2(483.9) 
Post-menopausal (1) 2865.4(477.2) 2707.2(406.9) 
 
